Antipsychotic induced weight gain (AIWG)
The use of antipsychotic medications has been associated with various metabolic side effects, including substantial weight gain in approximately 30% of treated patients. The primary goal of our ongoing research on antipsychotic-induced weight gain (AIWG) is to identify gene variants (i.e. genetic biomarkers) that may contribute to this phenotype in patients, and thus, be used to predict AIWG.
Our research has revealed significant associations between AIWG and polymorphisms of the cannabinoid-1-receptor (Tiwari et al., 2010, PubMed) , melanocortin-4-receptor gene (Chowdhury et al., 2013,PubMed), Neuropeptide-Y gene (Tiwari et al., 2013, PubMed), mitochondrial genes (Goncalves et al., 2014, PubMed), and immune genes (Fonseka et al., 2015, PubMed). We are currently developing an algorithm that will incorporate these genes, along with clinical and demographic risk factors, to develop a genetic risk prediction model for clinical application.